Macular Degeneration & Vision stem cell therapy — your questions answered (2026)

About stem cell therapy for Macular Degeneration & Vision

Age-related macular degeneration (AMD) and inherited retinal diseases can damage photoreceptors or the retinal pigment epithelium (RPE), but they are distinct conditions with different causes and established management. Investigational cell approaches include RPE or retinal progenitor products derived from sources such as induced pluripotent stem cells (iPSC). Laboratory differentiation or integration hypotheses do not establish restored vision in people. Product identity, surgical route, immune risk and disease stage are critical. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Macular Degeneration & Vision

Human retinal cell-therapy studies are early and heterogeneous, involving different diseases, cell products, surgical routes and endpoints. Small-cohort safety observations and exploratory visual changes do not establish durable vision stabilisation or restoration. Imaging, light sensitivity and visual-acuity measures should not be merged into a single response claim. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational retinal cell procedures can involve separate charges for surgery, imaging, laboratory testing, immunological monitoring, travel and treatment of complications. Prices do not indicate regulatory approval or expected visual benefit, and bilateral treatment should not be assumed appropriate. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Established retinal care must not be delayed.

Can stem cells restore vision?

Cell therapy for Macular Degeneration & Vision may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Wet vs dry AMD?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Is it experimental?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Macular Degeneration & Vision programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Macular Degeneration & Vision (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Macular Degeneration & Vision overview · Macular Degeneration & Vision cost →